Nuvectra Corporation

Nuvectra — Investor Presentation (August 2018)

26 slides from Nuvectra's investor presentation, Aug 15, 2018

  1. Slide 1: Nuvectra: New Directions in Neurostimulation

    NUVECTRA NEW DIRECTIONS IN NEUROSTIMULATION August 2018 Investor Presentation Scott Drees, CEO Walter Berger, COO & CFO

  2. Slide 2: Legal Disclaimer

    eee LEGAL DISCLAIMER ‘This presentation contains “Tonward-looking statements,” including statements we make regarding the outlock for Nuvectra™ as an independent public sraded company. Fonvard- looking statements are based only on our current bells, expectations and assumptions regarding the future

  3. Slide 3: Significant revenue growth opportunity in large, established markets

    @ Significant revenue growth opportunity in large, established markets (/) Neurostimulation platform technology and IP for multiple indications @®~$50M+ annualized consolidated revenue run-rate in Q2'18' @Proven commercial success 2,000+ US Algovita implants @Advancing SCS post-market clinical data

  4. Slide 4: Large & Growing Target Markets; Platform Technology

    ~$3.4B” Large & Growing Target Markets Platform Technology + Expansive IP Portfolio + Access to multiple markets & indications + Partnering opportunities (i.e., DBS development agreement) * Spinal Cord Stimulation (SCS) * Sacral Neuromodulation (SNM) * Deep Brain Stimulation (DBS) Algovita SCS Syste

  5. Slide 5: Neurostimulation Target Market Opportunities

    NEUROSTIMULATION TARGET MARKET OPPORTUNITIES SCS MARKET @ SNM MARKET @ DBS MARKET @) ABT y BSx ~ ABT f a = MDT BSX \ NvRO = MDT NN | NVIR CHRONIC PAIN BLADDER & BOWEL CONTROL MOVEMENT DISORDERS ~$2.0B ~$690M ~$650M ~11% CAGR ~8% CAGR ~9% CAGR 2020 2016 2017 2018 2019 2020 2017 2018 2019 2020 veka ch

  6. Slide 6: Platform Designed for Multiple Indications

    PLATFORM DESIGNED FOR MULTIPLE INDICATIONS NUVECTRA IMPLANTABLE PULSE LEADS PHYSICIAN & PATIENT PROPRIETARY GENERATOR PROGRAMMERS PROCESSORS BROAD IP PORTFOLIO ISSUED: SS ——<— ISSUED: PENDING: L2] PENDING:

  7. Slide 7: Management Team

    Scott Drees CEO & DIRECTOR * QIG Group, CEO & Founding Partner + Founding Division President, ‘Advanced Neuromodulation Systeme Inc. (ANSI) + Prior experience: St. Jude Medical, Boston Scientific, J & J + 37yre, implantable med. device experience; 22 years in neuromodulation NUVECTRA Walter Berger C

  8. Slide 8: SCS: Our First Opportunity

    CC ee SCS: OUR FIRST OPPORTUNITY NUVECTRA PROBLEM Chronic pain is a significant Paradigm is changing: medical, economic and social problem. pharmaceuticals to electroceuticals. © CHRONIC PAIN (?) © SPINAL CORD STIMULATION + ~1.5B worldwide suffer from chronic pain + Next gen technology shown to impr

  9. Slide 9: Algovita SCS System

    ALGOVITA SCS SYSTEM Designed to improve outcomes. NUVECTRA

  10. Slide 10: Powerful IPG Therapy Delivery

    POWERFUL IPG THERAPY DELIVERY © FOUR STIMULATION MODES * High Fidelity Tonic * Burst * Ultra Long PW * High Frequency 66\/6 @ 6 Nuvectra Medtronic Abbott Boston Scientific CONFIGURATION 3x8 and 2x12 28 a8 4x8 CHANNELS: 6 6 2 POWER SOURCES 1 1 2 ‘MAX AMPLITUDE 255 Ma 255mA 255mA FREQUENCY 40-1,200 Hz

  11. Slide 11: World's first stretchable leads

    World's first stretchable leads. © KEY CAPABILITIES + Lead elongation (stretchability) + Kink-resistant + Reduce lead migration (13%)(*) + Reduce lead breakage (9%)\") * Increase spinal coverage ‘STRANDED WIRE 8-Electrode Leads & COMPETITORS N UVECT RA (1) Cameron etl, 204. Seay 8 ERcacy of SCSin Cr

  12. Slide 12: A New Generation of Surgical/Paddle Leads

    ANEW GENERATION OF SURGICAL/PADDLE LEADS © KEY CAPABILITIES Aticulating hinge Reduced size and volume improves safety profile” Steerable stylet and posterior stabilizing ribs Multi-midline electrode configuration Stretchable lead body and single lead tail | © TWO PLACEMENT OPTIONS: | * Traditional p

  13. Slide 13: Simplifying Programming Complexity & Patient Interaction

    SIMPLIFYING PROGRAMMING COMPLEXITY & PATIENT INTERACTION CLINICIAN PATIENT + Algorithmic-driven + Key fob patient controller programming with direct * Icon based touch screen patient input + Wireless telemetry + Precise current steering in * Combination recharger—- 1% increments patient controller +

  14. Slide 14: Quarterly revenue growth by Algovita, NeuroNexus and Services

    me mNeuroNexus $134 a m Services $12.0 mAlgovita $10.6 $10 = eS $8 $7.2 STS. 5 5 $5.0 & vi $3.8 2 son, 828 : bel so | ais ata Tatts ALGOVITA YoY growth é 2% o19% | cum | 716% | oem | ate | ~_4t0% 160% | 110% QoQ sequential growth - 37% 105% 73% 68% 62% 15% 65% 13% 27% NUVECTRA YoY growth - 1% 196% 2

  15. Slide 15: U.S. Commercialization

    U.S. COMMERCIALIZATION © HIRE PROVEN SELLING TEAM Sales management, national account coverage, direct reps, sales agents, clinical specialists + U.S. Algovita sales team + Increased to ~60 territories * Increased to ~10 regions + Continued expansion into new territories © QUARTERLY REP PRODUCTIVITY?

  16. Slide 16: Four-Arm Post-Market Study

    ee NUVECTRA © INITIAL STUDY ARM & TIMING Compare outcomes: high fidelity tonic vs. ultra long pulse width 60 patients @ 12 sites IRBs established, sites & patient enrollment initiated Advance data through publication and presentation © FOUR-ARM POST-MARKET STUDY + Designed to study real-world ‘outco

  17. Slide 17: Virtis SNM System: Not Approved in the U.S. or EU

    = Not Approved in = the U.S. or EU NUVECT RA | wrevecsensss sso t cmc ei te Ut Ss ote Eats Ui ‘7

  18. Slide 18: Virtis Market Opportunity and Commercial Strategy

    © MARKET OPPORTUNITY + ~400M candidates worldwide” + ~$690 million market?) * 20+ years proven efficacy * 225,000 implants worldwide?) + Established reimbursement © COMMERCIAL STRATEGY + Awaiting FDA response to regulatory resubmission * Build Urology / UroGyn focused sales reps + Leverage existing

  19. Slide 19: Virtis: A New Generation of Lead Design

    VIRTIS: A NEW GENERATION OF LEAD DESIGN NUVECTRA » Se A CORE ADVANTAGES oA > 2 * Two leads ; * Stretchable * Reinforced lead body SN ! * Anchoring mechanism (fins vs. tines) = Michele Spinelli, MD Steven Siegel, MD N UVECT RAV Now: The Vite Syme nt esroved fr comme darter nthe Uned Sates ore Evconsn

  20. Slide 20: Virtis Competitive Comparison

    VIRTIS COMPETITIVE COMPARISON 2) MMR CONDITIONAL, # OF LEADS LEAD FIXATION REINFORCED LEAD BODY PATIENT CONTROLLER: BATTERY ‘STIM OUTPUT POWER SOURCES CURRENT STEERING COMMUNICATION IPG VOLUME NUVECTRA : Virtis™ Full Body / Head ® lord Fins Yes: Braid Key Fob Rechargeable Current l 19.5c¢ | InterSti

  21. Slide 21: Strategic Development Agreement: Aleva Neurotherapeutics

    STRATEGIC DEV EP OPMENT AGREEMENT! ALEVA NEUROTHERAPEUTICS AGREEMENT * Development agreement through 2018) + Nuvectra to license platform of IPG and programmers to Aleva for royalties + Aleva provides MEMS technology with directSTIM directional DBS lead + Field of use: DBS for Parkinson's Disease (P

  22. Slide 22: Frost & Sullivan 2017 New Product Innovation Award

    BT seo | THANK YOU! (Sa @ = = NUVECTRA ; F RiOgSale SU LelgiiVeAGN FROST @ SULLIVAN Nuvectra’s Spinal Cord Stimulator See Receives Frost & Sullivan's AwaRD 2017 New Product Innovation Award SPINAL CORD STIMULATION i

  23. Slide 23: CE Mark: Algovita MR Conditional Regulatory Strategy

    Cel MARK: ALGOVITA MR COON REGULATORY STRATEGY , Boston, Abbott ! Medtronic Scientific a nevro ~NUVECTRAC Inelis™ & Restore _ Spectra™ & Specta 2 m1 a aa ga | Ear Soe Montage ProligSMRI™ Procite Senza Noovia ‘APPROVAL Full Body Full Body Head & Extremities Full Body Full Body Full Body‘) STRENGTH if

  24. Slide 24: FDA: Algovita MRI Conditional Regulatory Strategy

    FDA: ALGOVITA MRI Cone ITION. REGULATORY STRATEGY Boston, Abbott 10004, Medtronic Setentific [=] aida NUVECTRA system itis™ ae Protégé MRI™ senza Agovi™ APPROVAL. Full Body Head & Extremities Full Body Full Body? STRENGTH terest Full Body Submission a 2017 2018 = v8 body MR cons sopovl exec based on

  25. Slide 25: Reduced length & thickness placement options

    Reduced length & thickness (<40% volume) 2 placement options _AdAw » — Traditional caudal level placement Ff — Direct visual placement (articulating hinge design) . Multi-midline electrode configuration Stylet and posterior stabilizing ribs —aheatharasn Stretchable lead body UI Een m oases station S

  26. Slide 26: Paddle Volume Matters

    Paddle Volume Matters gBostong. Medtronic Sr juve Meoieat | NUVECTRA’ | Configuration | 2x8 axe ze sos | ses as | oxo 402 [fume tee) or 09 08 16 13 9 | ea7 oss] Paddle nm) | x45 Ox60—| 76x50 10x04 | 19x57 11x46 | G6x64 x08 Height (mm) am ee eee dees = 1mm NUVECTRA 26

Nuvectra — Investor Presentation (August 2018) on 6ix